Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863406 | 1.00 | MAPK14 (0.37) | MAPK14CCNKCDK12JAK2NTRK1 | |
| SCHEMBL4793059 | 0.96 | JAK2 (0.35) | MAPK14CCNKCDK12JAK2NTRK1 | |
| SCHEMBL3864307 | 0.78 | DGAT1 (0.42) | MAPK14DGAT1 | |
| SCHEMBL31411454 | 0.67 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL15906056 | 0.67 | MAPK14 (0.47) | MAPK14JAK2NTRK1 | |
| SCHEMBL31411444 | 0.66 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL4014501 | 0.66 | BRD4 (0.38) | MAPK14DGAT1 | |
| SCHEMBL4013172 | 0.66 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL18812550 | 0.65 | MAPK14 (0.46) | MAPK14JAK2NTRK1 | |
| SCHEMBL16429533 | 0.64 | MAPK14 (0.47) | MAPK14JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601726-B2 | Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601726-B2 | Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K7 | MAPK14 36/4885CCNK 387/4885CDK12 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.